HeartBeam 12-Lead ECG Synthesis Software
Software that synthesizes a 12-Lead ECG from HeartBeam's 3-Lead recording device
Software · Cloud SaaSCompany source
Company profile
About HeartBeam
HeartBeam, Inc. has developed the first portable, cable-free ECG system capable of synthesizing a 12-lead ECG for the assessment of arrhythmias. The company's flagship product, the HeartBeam AIMIGo, is a credit card-sized device that captures the heart's electrical signals from three dimensions and synthesizes them into a 12-lead ECG using a personalized transformation matrix. Unlike traditional 12-lead ECGs that require healthcare professionals and are impractical for at-home use, HeartBeam's system enables patients to capture symptoms wherever they are, providing clinical-grade data that clinicians trust. The device uses 5 electrodes to record 3-lead (in three-directions) electrocardiogram data, which is then transmitted to the HeartBeam cloud where on-call physicians can review recordings and follow up with patients. The technology was created by Dr. Branislav Vajdic, co-inventor of flash memory, in collaboration with a Harvard-Beth Israel cardiologist and two nuclear physicists. HeartBeam's approach delivers exceptional data fidelity through a patient-friendly system that simplifies access to actionable synthesized 12-lead ECG results, especially upon symptom onset when minutes matter. The company is leveraging artificial intelligence to analyze data-rich signals with plans to improve diagnostic accuracy, track cardiac trends over time, and detect subtle changes that could signal early warning signs. The technology is protected by over 20 issued patents and serves as a platform technology with broad applications including extended wear patches, watches, continuous monitoring systems, and deep learning solutions.
Company description HeartBeam official website
Primary marketCardiology & Cardiovascular Health
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at HeartBeam?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Arrhythmias
- Atrial fibrillation
- Atrial flutter
- Atrial premature complexes
- Coronary occlusions
- Myocardial infarction (in development)
- Sinus arrhythmia
- Sinus bradycardia
- Sinus tachycardia
- Ventricular premature complex
Who it serves
- Healthcare facilities
- Patients
- Physicians
Deployment & integration
Cloud Saas · Hybrid deployment with recorded integration context.
Geographic context
MarketsInternational markets (implied) · United States (limited - FDA cleared but 12-lead synthesis not available for sale)
Company sourceOfficial website
Company milestones
Platform expansion
FDA clearance for HeartBeam System 3-lead ECG recorder and 12-lead synthesis software. Positive AI results presented at EHRA. Published study in JACC: Advances demonstrating equivalence to standard 12-lead ECG.
Partnerships
Recorded partners
- Harvard-Beth Israel (technology development collaboration)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
HeartBeam AI
AI-powered cardiac analysis for detection of complex arrhythmias and heart attacks
Software · Cloud SaaSCompany source
HeartBeam AIMIGo
First portable, cable-free ECG system capable of synthesizing a 12-lead ECG for arrhythmia assessment
Device · HybridCompany source
HeartBeam Ischemia Detection
Heart attack detection technology for remote coronary occlusion identification
Software · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
A Morphology-Preserving Algorithm for Denoising of EMG-Contaminated ECG Signals.IEEE open journal of engineering in medicine and biology · Jan 1, 2024
Coronary Artery Occlusion Detection Using 3-Lead ECG System Suitable for Credit Card-Size Personal Device Integration.JACC. Advances · Aug 1, 2023
A Database of Simultaneously Recorded ECG Signals With and Without EMG Noise.IEEE open journal of engineering in medicine and biology · Jan 1, 2023
Regulatory strategies for early device development and approval.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · May 1, 2022
Clinical validation
Clinical-trial records
HeartBeam ECG RegistryNCT07501299 · Sponsor · RECRUITING
ALIGN-ACS Pilot StudyNCT07715474 · Sponsor · ACTIVE NOT RECRUITING
Heart Rate and Breathing Effects on Attention and MemoryNCT05602220 · Mentioned · COMPLETED
AK+ Guard™ Pilot Study in Chronic Kidney Disease: Outpatient Diagnostic Accuracy and Remote MonitoringNCT07210021 · Mentioned · RECRUITING
AIMIGo 12L ECG Synthesis Software Pivotal Study for Arrythmia DetectionNCT06123130 · Sponsor · COMPLETED
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Equivalent to 12-lead ECG in identifying coronary occlusions
Study published in JACC: Advances
High accuracy (AUC) for coronary occlusion detection
Comparison to standard 12-lead ECG
Improved detection of atrial flutter over single-lead ECGs
HeartBeam AI combined with VCG
Piedmont Heart Institute
Clinical validation of cable-free portable synthesized 12-lead ECG system for at-home arrhythmia detection
Demonstrated HeartBeam's synthesized 12-lead ECG can support diagnosis of arrhythmias similar to standard 12-lead ECGs
Mount Sinai Hospital
Deep learning algorithm for atrial flutter and atrial fibrillation detection
HeartBeam AI outperforms expert panel of electrophysiologists in detecting atrial flutter and outperforms single-lead ECG
Beth Israel Deaconess Medical Center
Coronary artery occlusion detection using 3-lead ECG system for heart attack identification
HeartBeam technology shown to be comparable to 12-lead ECG in identifying coronary occlusions
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from HeartBeam
Recent articles published on HeartBeam's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Cardiology & Cardiovascular Health
Companies applying AI to cardiovascular disease detection, ECG/EKG analysis, heart failure management, cardiac imaging, arrhythmia detection, or cardiovascular risk assessment. Includes AI-powered cardiac diagnostics, non-invasive hemodynamic monitoring, and tools for early detection and personalized management of heart conditions.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.